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Reasons for ineligibility n

After patients identified N=79
No current positive symptoms of psychosis or problems 21 (26·6%) Dose of clozapine below 400mg and not limited due to side effects 16 (20·3%)
Lacking capacity to consent 9 (11·4%) Current CBT or CBT in past year 8 (10·1%)
Never taken clozapine 7 (8·9%)
Diagnosis not schizophrenia spectrum 7 (8·9%)
Discontinued clozapine ˃ 2 years ago 6 (7·6%)
Moved out of area 2 (2·5%)
Diagnosis of a developmental disability 1 (1·3%)
Not English speaking 1 (1·3%)
Deceased before consented 1 (1·3%)
After patients found to be eligible N=47
Below threshold on the Positive and Negative Syndrome Scale 40 (85·1%)
Diagnosis not schizophrenia spectrum 2 (4·3%)
Lacking capacity to consent 2 (4·3%) Dose of clozapine below 400mg and not limited due to side effects 1 (2·1%)
No current positive symptoms of psychosis or problems 1 (2·1%)
Unable to complete the baseline assessment 1 (2·1%) 
